Here are relevant reports on : oral-contraceptive-market
-
Veterinary Biologics Market by Product (Monoclonal Antibodies, Diagnostic Kits, Immunoglobulins & Antitoxins), RoA (Injectable, Oral), Application (Infectious Disease Prevention, Dermatology, Pain Management), Animal, End User - Global Forecast to 2030
The global veterinary biologics market, valued at US$2.61 billion in 2024, stood at US$2.72 billion in 2025 and is projected to advance at a resilient CAGR of 5.2% from 2024 to 2030, culminating in a forecasted valuation of US$3.51 billion by the end of the period. The market growth is fueled by increasing demand for effective animal therapeutics, rising populations of livestock and companion animals, and greater awareness of animal health and disease prevention.
- Published: October 2025
- Price: $ 4950
- TOC Available:
-
Humectants Market by Type (Sugar Alcohol, Glycerol, Alpha Hydroxy Acid & Polysaccharides, Glycols), Application (Food & Beverages, Oral & Personal Care, Pharmaceuticals, Animal Feed), Source (Synthetic, Natural), and Region - Global Forecast to 2022
The humectants market is projected to reach USD 26.27 Billion by 2022, at a CAGR of 7.0% from 2017, in terms of value. In terms of volume, the market is projected to reach 14,741.6 KT by 2022, at a CAGR of 3.9% from 2017. Key players such as Cargill (U.S.), The Dow Chemical Company (U.S.), Archer Daniels Midland Company (U.S.), E. I. du Pont de Nemours and Company (U.S.), and Roquette Frères (France) have been profiled in the report. These leading players have adopted various strategies such as expansions & investments, mergers & acquisitions, and new product launches to explore new and untapped markets, expanding in local areas of emerging markets, and developing a new customer base for long-term client relationships. This has not only enabled the key players to expand their geographical reach, but has also reinforced their market position by gaining a larger share in terms of revenues and product portfolios.
- Published: July 2017
- Price: $ 4950
- TOC Available:
-
Feed Anticoccidials Market by Livestock (Poultry, Ruminant, Swine), Type (Monensin, Salinomycin, Narasin, Diclazuril), Form (Dry, Liquid), Source (Chemical, Natural), Mode of Consumption (Oral, Injection) And Region - Global Forecast to 2025
The feed anticoccidials market is estimated to account for USD 331 million in 2019 and is projected to reach USD 429 million by 2025, at a CAGR of 4.4% during the forecast period. Elanco Animal Health (US), Huvepharma (Bulgaria), Phibro Animal Health (US), Ceva Animal Health (France), Zoetis (US), Impextraco (Belgium), Kemin Industries (US), Merck Animal Health (US), Virbac SA (France), Zydus Animal Health (India), Bioproperties Pty. Ltd. (Australia), and Qilu Animal Health Products Co. Ltd. (China).
- Published: July 2019
- Price: $ 4950
- TOC Available:
-
Asia Pacific Animal Parasiticides Market by Type [Ectoparasiticides (Pour-ons & Spot-ons, Dips), Endoparasiticides (Oral Liquids, Injectables, Feed Additives), Endectocides], Animal Type (Companion Animals, Livestock), End User - Forecast to 2031
The Asia Pacific animal parasiticides market, valued at USD 2.12 billion in 2025, stood at USD 2.26 billion in 2026 and is projected to advance at a resilient CAGR of 7.2% from 2026 to 2031, culminating in a forecasted valuation of USD 3.20 billion by the end of the period. The Asia Pacific animal parasiticides market is growing due to rising levels of parasite infestation among livestock and companion animals, expanding animal populations, and greater focus on preventive animal healthcare.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Animal Antibiotics and Antimicrobials Market by Product (Tetracycline, Penicillin, Sulfonamide, Macrolide, Cephalosporin, Lincosamide), Mode of Delivery (Premixes, Oral Solution, Injection), Animal (Food producing & Companion) & Region - Global Forecast to 2026
The global animal antibiotics market growth is primed to transition from $4.7 billion in 2021 to $5.6 billion by 2026, showcasing a strong CAGR of 3.6%. Market growth can largely be attributed to the rising demand for animal-derived food products, increasing incidence of zoonotic diseases, and the implementation of regulations to prevent the spread of animal diseases.
- Published: March 2021
- Price: $ 4950
- TOC Available:
-
North America Vaccines Market by Technology (Conjugate, Recombinant, Inactivated, Live Attenuated, Viral Vector), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, Hepatitis, MMR), Route of Administration (IM, SC, Oral) - Forecast to 2030
The North America vaccines market, valued at US$25.95 billion in 2024, stood at US$25.29 billion in 2025 and is projected to advance at a resilient CAGR of 7.1% from 2025 to 2030, culminating in a forecasted valuation of US$35.68 billion by the end of the period. The vaccines market is growing rapidly, driven by swift global vaccine development and commercialization, higher rates of infectious diseases necessitating preventive vaccines, expanded immunization initiatives, innovations in vaccine technology, and increased government funding and investments for novel vaccines against diverse diseases.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Syringes Market Size by Type (General & Specialized Syringes (insulin, tuberculin)), Usability (Sterilizable/reusable (hypodermic, oral) & Disposable Syringes (conventional, safety, prefilled)), Material (Glass & Plastic Syringes)- Global Forecast to 2021
The global syringes market size is projected to grow at a CAGR of 8.7%. High prevalence of chronic diseases across the globe, rising geriatric population, increasing adoption of safety syringes, technological advancements, and increasing demand for vaccines are supporting the market growth of syringes. However, high cost of safety syringes and increasing incidence of needle stick injuries are the major challenges in global Market.
- Published: November 2016
- Price: $ 4950
- TOC Available:
-
Vitamin D Therapy Market by Route of administration (Oral, Parenteral), Age Group (Children, Adult, Senior Adult), Purchase Pattern (OTC, Prescription), Application (Osteoporosis, Rickets, Autoimmune Disorder, Skin Diseases) - Global Forecast to 2024
The vitamin D therapy market is projected to reach USD 3.3 billion by 2024 from USD 1.9 billion in 2019, at a CAGR of 11.6% during the forecast period. Growth in this market is largely driven by the growing awareness about vitamin D deficiency and the presence of a large target patient population. On the other hand, the fortification of foods is likely to challenge the growth of this market. Some of the major players in this market include Abbott (US), Sanofi (France), GlaxoSmithKline plc (UK), Pfizer Inc. (US), Merck & Co., Inc. (US), Torrent Pharmaceuticals Ltd. (India), Novartis International AG (Switzerland), Alkem Laboratories (India), Sun Pharmaceutical Industries Ltd. (India), and Cadila Healthcare Ltd. (India).
- Published: April 2019
- Price: $ 4950
- TOC Available:
-
Migraine Drugs Market by Product Type (Acute migraine treatment, Preventive migraine treatment), Route of administration (Oral, Injection, and Others), and End User (Hospital pharmacies, Retail pharmacies, Online pharmacies) - Global Forecast to 2023
The global Migrane Drugs market is expected to reach USD 3.96 billion by 2023 from USD 1.95 million in 2018, growing at a CAGR of 15.2%. Increasing awareness about novel therapies, launch of Calcitonin Gene-related Peptide (CGRP), increasing incidence of migraines and launch of new drugs are some of the major factors driving the growth of the global suture anchor market. These driving factors consequence to the rapid adoption of these new drugs, thus propelling the market growth.
- Published: May 2026
- Price: $ 4950
- TOC Available:
-
Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics, Synbiotics, Diagnostics), Disease (Infectious, Gastrointestinal), Route (Oral, Rectal), CDMO (Formulation, Strain Engineering), Type (BCT/FMT, Live Bacteria) - Global Forecast to 2031
The global human microbiome market, valued at USD 0.91 billion in 2024, stood at USD 1.40 billion in 2025 and is projected to advance at a resilient CAGR of 31.0% from 2025 to 2031, culminating in a forecasted valuation of USD 7.09 billion by the end of the period. North American market held the largest share during the forecast period due to the rising investments by governments and industries, and presence of a strong human microbiome ecosystem supporting innovation in this field.
- Published: August 2025
- Price: $ 4950
- TOC Available:
Records 31 to 40 of 50
